psoriasis drugs

Psoriasis and atopic dermatitis respond to IL-17 creamNitric oxide-releasing cream that targets IL-17 moving toward clinical trials.
TNF inhibitor treatment tacticsWith a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
TNF alfpha inhibitor safety, efficacy data growsLong-term follow-up studies and drug registries continue to deliver reassuring data regarding the safety and efficacy of TNF inhibitors, an expert says.
Psoriasis drug approved with boxed warningA new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.
The oral pipeline for psoriasisOral options in the pipeline for psoriasis show promise.
Payers want more dataA pioneering summit between healthcare payers and groups pursuing standardized outcome measures in dermatology has revealed that payers want outcome measures that are published, universally accepted and practical both for clinicians and payers.
The implications in the future of biosimilarsThe FDA is evaluating biosimilar medications for use in the United States. The approval of these medications in the next few years could mean big changes for dermatologists and their psoriasis patients
How to mitigate apremilast’s gastrointestinal side effectsPatients with psoriasis and psoriatic arthritis who take apremilast can present uncomfortable side effects. How to address key concerns.
What looks promising in the pipeline for psoriasisAs research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.